Mirae Asset Global Investments Co. Ltd. Buys 1,779 Shares of LivaNova PLC (NASDAQ:LIVN)

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 6.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,981 shares of the company’s stock after acquiring an additional 1,779 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of LivaNova worth $1,499,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Lazard Asset Management LLC acquired a new position in shares of LivaNova in the second quarter valued at approximately $46,000. Headlands Technologies LLC acquired a new position in shares of LivaNova in the third quarter valued at approximately $72,000. Point72 Middle East FZE acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $72,000. Picton Mahoney Asset Management acquired a new position in shares of LivaNova in the third quarter valued at approximately $91,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of LivaNova by 16.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company’s stock valued at $147,000 after buying an additional 408 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LIVN shares. Barclays boosted their price target on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Mizuho reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and set a $72.00 target price on shares of LivaNova in a research note on Wednesday, March 20th. Robert W. Baird upped their target price on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 22nd. Finally, StockNews.com cut LivaNova from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $64.40.

LivaNova Stock Down 0.8 %

NASDAQ LIVN opened at $52.33 on Monday. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $59.86. The stock has a market capitalization of $2.82 billion, a PE ratio of 163.54 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The business has a fifty day moving average price of $53.58 and a two-hundred day moving average price of $50.52.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. During the same period in the prior year, the company earned $0.81 EPS. LivaNova’s revenue was up 12.8% compared to the same quarter last year. Equities analysts expect that LivaNova PLC will post 3.01 earnings per share for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.